Edwards Lifesciences Corporation (EW) stock — is it a good business?

Edwards Lifesciences Corporation (EW) stock — is it a good business? — InspectStocks

Just reported

Q3 2026 results

From Edwards Lifesciences's results release of November 4, 2026; its quarterly report has since been filed.

Revenue
Actual
$1.72B
+10% y/y
-1.5% q/q
Guided
$1.67B
midpoint
Above guide+2.7%
EPS, GAAP
Actual
$0.53
+6.0% y/y
+26% q/q
Guided
—
No guide given
Operating income, GAAP
Actual
$299.1M
-2.6% y/y
-42% q/q
Guided
—
No guide given

Company outlook

Q4 2026

Revenue$1.67B – $1.75B+8.9% y/y First given

Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.

How it makes money

Catheter-delivered aortic valve replacement72%
Catheter-delivered mitral and tricuspid valve repair and replacement11%
Surgical heart valve products16%

Shares of revenue are estimates for nine months ended September 30, 2026, not figures from a filing.

Competes with

What it sells5

SAPIEN
A family of tissue valves delivered through a catheter to replace a diseased aortic valve; some systems are also used for pulmonary valve replacement.
PASCAL
A catheter-delivered device that helps bring together the leaflets of a leaking mitral or tricuspid valve.
EVOQUE
A tissue valve delivered through a catheter to replace a leaking tricuspid valve.

Show 2 more

SAPIEN M3
A tissue valve delivered through a catheter to replace a diseased mitral valve.
INSPIRIS RESILIA, KONECT RESILIA, and MITRIS RESILIA
Surgical tissue valve products for aortic and mitral valve replacement; KONECT is a tissue valve conduit used in complex combined procedures.

Who buys it3

Hospitals and health systems buy devices directly from Edwards sales teams or through distributors; in the United States, sales are mainly direct.
Hospital purchasing groups and healthcare networks negotiate supplier contracts on behalf of hospitals.
Heart specialists, including cardiac surgeons and interventional cardiologists, use the devices and take part in choosing treatments.

What it stands on, and what could break it

What the business leans on

1A large part of the business depends on hospitals adopting catheter-delivered aortic valve replacement and on clinicians choosing Edwards devices.
2Sales depend in part on government and private insurers covering procedures and paying hospitals enough to support their use.
3Some materials and components come from single-source suppliers; switching critical suppliers can require lengthy regulatory review.
4The company relies on clinical studies and regulatory clearances or approvals to bring devices to market and expand their permitted uses.

What could go wrong

1If clinical studies do not show the needed results, or regulators do not approve new devices or uses, Edwards may be unable to sell those products or expand their use.
2Manufacturing, quality, safety, or delivery problems at Edwards or its suppliers could interrupt access to implanted heart valves and other devices.
3If insurers or government health programs restrict coverage or reduce payments, hospitals may buy fewer devices or seek lower prices.

Full financial statements →

About Edwards Lifesciences Corporation

Edwards makes devices that replace or repair damaged heart valves. Some are delivered through a catheter, a thin tube passed through a blood vessel, while others are implanted during open-heart surgery. Hospitals and heart specialists use these devices to treat diseases affecting the aortic, mitral, and tricuspid valves.

Head office: Irvine, California, United States
Founded: 1958
Employees: Approximately 16,000 (December 31, 2025, medium)
Listed on: New York Stock Exchange
Financial year ends: December 31

Built from Edwards Lifesciences Corporation’s own filings with the U.S. Securities and Exchange Commission (SEC). Figures are as reported, with per-share history restated onto today’s share basis. This describes a business — it is not investment advice and not a recommendation to buy or sell anything.

Just reported

Q3 2026 results

From Edwards Lifesciences's results release of November 4, 2026; its quarterly report has since been filed.

Revenue
Actual
$1.72B
+10% y/y
-1.5% q/q
Guided
$1.67B
midpoint
Above guide+2.7%
EPS, GAAP
Actual
$0.53
+6.0% y/y
+26% q/q
Guided
—
No guide given
Operating income, GAAP
Actual
$299.1M
-2.6% y/y
-42% q/q
Guided
—
No guide given

Company outlook

Q4 2026

Revenue$1.67B – $1.75B+8.9% y/y First given

Keep exploring

The themes Edwards Lifesciences is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.

The theme it is part of

Highest-graded in Medical Devices

Graded A or B and worth $2B or more: A first, then the largest.

Grade rose recently in Healthcare

Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.

How it makes money

Catheter-delivered aortic valve replacement72%
Catheter-delivered mitral and tricuspid valve repair and replacement11%
Surgical heart valve products16%

Shares of revenue are estimates for nine months ended September 30, 2026, not figures from a filing.

Competes with

What it sells5

SAPIEN
A family of tissue valves delivered through a catheter to replace a diseased aortic valve; some systems are also used for pulmonary valve replacement.
PASCAL
A catheter-delivered device that helps bring together the leaflets of a leaking mitral or tricuspid valve.
EVOQUE
A tissue valve delivered through a catheter to replace a leaking tricuspid valve.

Show 2 more

SAPIEN M3
A tissue valve delivered through a catheter to replace a diseased mitral valve.
INSPIRIS RESILIA, KONECT RESILIA, and MITRIS RESILIA
Surgical tissue valve products for aortic and mitral valve replacement; KONECT is a tissue valve conduit used in complex combined procedures.

Who buys it3

Hospitals and health systems buy devices directly from Edwards sales teams or through distributors; in the United States, sales are mainly direct.
Hospital purchasing groups and healthcare networks negotiate supplier contracts on behalf of hospitals.
Heart specialists, including cardiac surgeons and interventional cardiologists, use the devices and take part in choosing treatments.

What it stands on, and what could break it

What the business leans on

1A large part of the business depends on hospitals adopting catheter-delivered aortic valve replacement and on clinicians choosing Edwards devices.
2Sales depend in part on government and private insurers covering procedures and paying hospitals enough to support their use.
3Some materials and components come from single-source suppliers; switching critical suppliers can require lengthy regulatory review.
4The company relies on clinical studies and regulatory clearances or approvals to bring devices to market and expand their permitted uses.

What could go wrong

1If clinical studies do not show the needed results, or regulators do not approve new devices or uses, Edwards may be unable to sell those products or expand their use.
2Manufacturing, quality, safety, or delivery problems at Edwards or its suppliers could interrupt access to implanted heart valves and other devices.
3If insurers or government health programs restrict coverage or reduce payments, hospitals may buy fewer devices or seek lower prices.

Full financial statements →

About Edwards Lifesciences Corporation

Head office: Irvine, California, United States
Founded: 1958
Employees: Approximately 16,000 (December 31, 2025, medium)
Listed on: New York Stock Exchange
Financial year ends: December 31

Q3 2026 results

Revenue

EPS, GAAP

Operating income, GAAP

Company outlook

How it makes money

Competes with

What it sells5

Who buys it3

What it stands on, and what could break it

What the business leans on

What could go wrong

About Edwards Lifesciences Corporation

Q3 2026 results

Revenue

EPS, GAAP

Operating income, GAAP

Company outlook

Keep exploring

The theme it is part of

Highest-graded in Medical Devices

Grade rose recently in Healthcare

How it makes money

Competes with

What it sells5

Who buys it3

What it stands on, and what could break it

What the business leans on

What could go wrong

About Edwards Lifesciences Corporation

Edwards Lifesciences Corporation

Keep exploring

The theme it is part of

Highest-graded in Medical Devices

Grade rose recently in Healthcare

Medical devices

Growth & cash — 5 of 5

Business trend

Share price and grade over time

Q3 2026 results

Revenue

EPS, GAAP

Operating income, GAAP

Company outlook

How it makes money

Competes with

What it sells5

Who buys it3

What it stands on, and what could break it

What the business leans on

What could go wrong

About Edwards Lifesciences Corporation

Q3 2026 results

Revenue

EPS, GAAP

Operating income, GAAP

Company outlook

Keep exploring

The theme it is part of

Highest-graded in Medical Devices

Grade rose recently in Healthcare

How it makes money

Competes with

What it sells5

Who buys it3

What it stands on, and what could break it

What the business leans on

What could go wrong

About Edwards Lifesciences Corporation

Edwards Lifesciences Corporation

Past performance

Keep exploring

The theme it is part of

Highest-graded in Medical Devices

Grade rose recently in Healthcare

Medical devices

Growth & cash — 5 of 5

Business trend

Share price and grade over time